GlassScriptPhysician profile
Linda M Laforce
NPI 1356330492
$6,136.50
in general payments reported to CMS, 2019-2025
50 companies · $161 in 2025
The $161 reported for 2025 was more than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $636 · 2022: $748 · 2023: $2,189 · 2024: $2,402 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,477 · Education: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,476.67 |
| Education | $275.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $548.66 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $493.42 | 2021-2024 | Lynparza, Enhertu, Imfinzi |
| Incyte Corporation | $395.71 | 2022-2024 | Jakafi, Monjuvi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $327.43 | 2021-2024 | Opdivo, Opdualag, Krazati |
| Novartis Pharmaceuticals Corporation | $322.05 | 2021-2025 | |
| Seagen INC. | $314.90 | 2021-2023 | Padcev, Tukysa |
| Celgene Corporation | $313.22 | 2022-2025 | Reblozyl, Pomalyst |
| Pfizer INC. | $244.67 | 2021-2024 | |
| Genzyme Corporation | $236.35 | 2021-2024 | |
| Karyopharm Therapeutics INC. | $188.78 | 2021-2024 | Xpovio |
| Glaxosmithkline, LLC. | $179.87 | 2021-2024 | Ojjaara, Jemperli, Zejula |
| Genentech USA, INC. | $176.17 | 2021-2024 | Phesgo, Rozlytrek, Avastin |
| Abbvie INC. | $169.84 | 2022-2025 | |
| Lilly USA, LLC | $162.71 | 2022-2024 | Verzenio, Jaypirca, Retevmo |
| Regeneron Healthcare Solutions, INC. | $162.69 | 2022-2025 | Libtayo |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $145.80 | 2022-2024 | Trodelvy |
| Novocure INC. | $145.63 | 2023-2024 | Optune Lua (Novottf-200t), Optune |
| Eisai INC. | $120.02 | 2022-2024 | |
| Puma Biotechnology, INC. | $118.74 | 2022-2024 | |
| Daiichi Sankyo INC. | $117.50 | 2021-2024 | Enhertu |
| Janssen Biotech, INC. | $109.18 | 2021-2025 | Rybrevant |
| Taiho Oncology, INC. | $108.64 | 2023-2024 | |
| Acrotech Biopharma INC. | $73.60 | 2021-2023 | Beleodaq |
| Sun Pharmaceutical Industries INC. | $68.98 | 2021-2024 | |
| Beigene USA, INC. | $59.81 | 2023-2024 | Brukinsa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.68 | 2021 | |
| Amgen INC. | $56.95 | 2021-2023 | Kyprolis, Blincyto, Lumakras |
| Sobi, INC | $56.04 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $55.92 | 2022-2023 | Imbruvica |
| Rigel Pharmaceuticals, INC. | $54.72 | 2023-2024 | Tavalisse, Rezlidhia |
| Adaptive Biotechnologies Corporation | $47.25 | 2022-2023 | Clonoseq |
| Takeda Pharmaceuticals U.S.A., INC. | $45.55 | 2022-2024 | Fruzaqla |
| Deciphera Pharmaceuticals INC. | $43.08 | 2023-2024 | Qinlock |
| Bayer Healthcare Pharmaceuticals INC. | $41.60 | 2023-2024 | |
| Astellas Pharma US INC | $41.27 | 2023-2024 | Xospata, Padcev |
| Alexion Pharmaceuticals, INC. | $39.04 | 2022-2024 | Ultomiris |
| Jazz Pharmaceuticals INC. | $35.03 | 2023-2024 | |
| Servier Pharmaceuticals LLC | $31.73 | 2023-2024 | |
| Dova Pharmaceuticals | $23.58 | 2021 | |
| Aveo Pharmaceuticals, INC. | $23.44 | 2023 | Fotivda |
| G1 Therapeutics, INC. | $23.26 | 2023 | Cosela |
| Array Biopharma INC | $21.07 | 2024 | Braftovi, Lorbrena |
| Cti Biopharma Corp. | $20.32 | 2022 | |
| Organon LLC | $20.13 | 2021 | |
| Blue Earth Diagnostics | $18.50 | 2023 | |
| Myriad Genetic Laboratories, INC. | $16.51 | 2023 | Precisetumor |
| Pharmaessentia USA Corporation | $15.58 | 2024 | Besremi |
| Adc Therapeutics America, INC. | $15.32 | 2024 | |
| Recordati_rare_diseases_inc. | $15.00 | 2023 | Sylvant |
| Eusa Pharma (US) LLC | $12.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Laforce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.